Medical College of Wisconsin, Milwaukee, WI, USA.
Curr Cardiol Rep. 2019 Aug 30;21(10):113. doi: 10.1007/s11886-019-1213-x.
Chronic kidney disease (CKD) is a highly prevalent condition that increases the incidence and complexity of acute coronary syndrome (ACS). The purpose of this review is to summarize current evidence, uncertainties, and opportunities in the management of patients with CKD and ACS, with a focus on revascularization.
Patients with CKD have been systematically under-represented or excluded from clinical trials in ACS. Available data, however, demonstrates that although patients with CKD and ACS benefit from revascularization, they are also less likely to receive recommended medical and revascularization therapies when compared to patients with normal kidney function. Despite the increased short-term risk of major morbidity and mortality, patients with CKD and ACS should be considered for an early invasive strategy while also trying to mitigate the risks of procedural related complications. Until evidence emerges from randomized clinical trials, the decision about revascularization strategy should involve multi-disciplinary collaboration, heart team consensus, and patient shared decision-making.
慢性肾脏病(CKD)是一种高发疾病,会增加急性冠状动脉综合征(ACS)的发病率和复杂性。本文综述的目的在于总结 CKD 和 ACS 患者管理方面的现有证据、不确定因素和机会,重点关注血运重建。
CKD 患者在 ACS 临床试验中系统地代表性不足或被排除在外。然而,现有数据表明,尽管 CKD 和 ACS 患者从血运重建中获益,但与肾功能正常的患者相比,他们接受推荐的药物和血运重建治疗的可能性更小。尽管短期发生严重不良事件和死亡的风险增加,但应考虑对 CKD 和 ACS 患者采取早期侵入性策略,同时尽量减少与操作相关的并发症风险。在随机临床试验产生证据之前,血运重建策略的决策应涉及多学科协作、心脏团队共识和患者共同决策。